BlackRock Investment Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

BlackRock Investment Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$665K	Buy	86,206 +282	+0.3%	+$2.59K	﹤0.01%	2926
2016 Q3	$982K	Buy	85,924 +22,967	+36%	+$267K	﹤0.01%	2684
2016 Q2	$775K	Buy	62,957 +3,792	+6%	+$46K	﹤0.01%	2813
2016 Q1	$598K	Buy	59,165 +10	+0%	+$117	﹤0.01%	2816
2015 Q4	$1.33M	Buy	59,155 +466	+0.8%	+$9.55K	﹤0.01%	2379
2015 Q3	$974K	Sell	58,689 -1,334	-2%	-$26.7K	﹤0.01%	2618
2015 Q2	$1.35M	Buy	60,023 +23,087	+63%	+$569K	﹤0.01%	2547
2015 Q1	$952K	Buy	36,936 +392	+1%	+$9.94K	﹤0.01%	2551
2014 Q4	$795K	Sell	36,544 -416	-1%	-$8.52K	﹤0.01%	2697
2014 Q3	$700K	Buy	36,960 +855	+2%	+$17.2K	﹤0.01%	2768
2014 Q2	$841K	Buy	36,105 +22,598	+167%	+$558K	﹤0.01%	2731
2014 Q1	$455K	Buy	13,507 +696	+5%	+$23.5K	﹤0.01%	3003
2013 Q4	$378K	Buy	12,811 +721	+6%	+$13.2K	﹤0.01%	3086
2013 Q3	$185K	Buy	+12,090	New	+$224K	﹤0.01%	3196

Other funds holding OMED

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock Investment Management's OMED Position: Q4 2016 in Review

BlackRock Investment Management increased its OncoMed Pharmaceuticals, Inc. (OMED) stake by 0.33% in Q4 2016, buying an estimated $2.59K and bringing the position to 86,206 shares worth $665K. The position accounts for ﹤0.01% of the portfolio, ranked #2926.

BlackRock Investment Management first reported a position in OMED in Q3 2013 and has held it in 14 quarters since. The position peaked at $1.35M in Q2 2015. 86 funds tracked by Wall St. Rank hold OMED as of Q4 2016.

BlackRock Investment Management held 86,206 shares of OncoMed Pharmaceuticals, Inc. worth $665K as of Q4 2016.
BlackRock Investment Management bought 282 OncoMed Pharmaceuticals, Inc. shares in Q4 2016, an estimated $2.59K.
OncoMed Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2926 holding.
BlackRock Investment Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and has held it in 14 quarters since.
BlackRock Investment Management's OncoMed Pharmaceuticals, Inc. position peaked at $1.35M in Q2 2015.
86 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.